Avadel markets products in the hospital and primary care spaces.

The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

[3] The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.

[7] In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor.

[8][9] In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate.